Literature DB >> 8474058

Methotrexate inhibits proliferation but not interleukin 1 stimulated secretory activities of cultured human synovial fibroblasts.

F A Meyer1, I Yaron, V Mashiah, M Yaron.   

Abstract

The effect of methotrexate (MTX) on proliferation and on interleukin 1 stimulated secretory activities of human synovial fibroblasts in culture was investigated. MTX caused a dose dependent inhibition of growth over the concentration range 0.07-2.2 microM with a half-maximal effect at 0.37 microM. INhibition was competitively relieved by coaddition of leucovorin. Cell growth was fully restored after MTX pretreatment of 24 h but not after 48 h, even on subsequent leucovorin addition. Cell viability was unaffected by MTX treatment. MTX had no effect on interleukin 1 stimulated production of prostaglandin E, hyaluronic acid and collagenase. Our results raise the possibility that one of the mechanisms contributing to the therapeutic effects of MTX in patients with rheumatoid arthritis may involve modulation of synovial fibroblast growth.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8474058

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

1.  Good clinical response to methotrexate treatment in a patient with fibroblastic rheumatism.

Authors:  Juliane Aline Paupitz; Jozélio Freire de Carvalho
Journal:  Rheumatol Int       Date:  2010-03-26       Impact factor: 2.631

2.  Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression.

Authors:  M F Neurath; K Hildner; C Becker; J F Schlaak; K Barbulescu; T Germann; E Schmitt; P Schirmacher; S Haralambous; M Pasparakis; K H Meyer Zum Büschenfelde; G Kollias; E Märker-Hermann
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

3.  Methotrexate modulates the expression of MMP-1 and type 1 collagen in dermal fibroblast.

Authors:  Layla Nabai; Ruhangiz T Kilani; Farzian Aminuddin; Yunyuan Li; Aziz Ghahary
Journal:  Mol Cell Biochem       Date:  2015-08-23       Impact factor: 3.396

4.  Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis.

Authors:  K Hildner; S Finotto; C Becker; J Schlaak; P Schirmacher; P R Galle; E Märker-Hermann; M F Neurath
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

Review 5.  Methotrexate in rheumatoid arthritis. An update.

Authors:  B Bannwarth; L Labat; Y Moride; T Schaeverbeke
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

6.  Divergent effects of methotrexate on the clonal growth of T and B lymphocytes and synovial adherent cells from patients with rheumatoid arthritis.

Authors:  A Nakajima; M Hakoda; H Yamanaka; N Kamatani; S Kashiwazaki
Journal:  Ann Rheum Dis       Date:  1996-04       Impact factor: 19.103

7.  Limited effect of anti-rheumatic treatment on 15-prostaglandin dehydrogenase in rheumatoid arthritis synovial tissue.

Authors:  Karina Roxana Gheorghe; Syed Sadique; Patrick Leclerc; Helena Idborg; Ivonne Wobst; Anca Irinel Catrina; Per-Johan Jakobsson; Marina Korotkova
Journal:  Arthritis Res Ther       Date:  2012-05-22       Impact factor: 5.156

8.  Administration of PDE4 inhibitors suppressed the pannus-like inflammation by inhibition of cytokine production by macrophages and synovial fibroblast proliferation.

Authors:  Katsuya Kobayashi; Toshio Suda; Haruhiko Manabe; Ichiro Miki
Journal:  Mediators Inflamm       Date:  2007       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.